The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Abstract
Background Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones. This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive allosteric modulator of γ-aminobutyric acid (GABA A ) receptors, for the treatment of post-partum depression. Methods For this double-blind, randomised, placebo-controlled trial, we enrolled self-referred or physician-referred female inpatients (≤6 months post partum) with severe post-partum depression (Hamilton Rating Scale for Depression [HAM-D] total score ≥26) in four hospitals in the USA. Eligible women were randomly assigned (1:1), via a computer-generated randomisation program, to receive either a single, continuous intravenous dose of brexanolone or placebo for 60 h. Patients and investigators were masked to treatment assignments. The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 h, assessed in all randomised patients who started infusion of study drug or placebo and who had a completed baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Patients were followed up until day 30. This trial is registered with ClinicalTrials.gov, number NCT02614547. Findings This trial was done between Dec 15, 2015 (first enrolment), and May 19, 2016 (final visit of the last enrolled patient). 21 women were randomly assigned to the brexa…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid antidepressant effects, along with previous brexanolone injection clinical trials, support the development of NAS GABAAR PAMs as PPD therapies and potential fast-acting antidepressants.37,38,53”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [37]
In the citing paper
“Moreover, the findings of this study, along with prior PPD studies,37,38 support the potential for the development and therapeutic use of NAS GABAAR PAMs in the treatment of PPD.”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [37]
In the citing paper
“Brexanolone injection, a NAS GABAAR PAM, demonstrated reductions in depressive symptoms in 3 double-blind, randomized, placebo-controlled trials and was approved by the US Food and Drug Administration for treatment of adults with PPD.37,38”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [37]
In the citing paper
“Extended release (60 h IV infusion) BRX demonstrated rapid, durable AD efficacy during phase I, II, and III clinical trials [181,182,183].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [181]
In the citing paper
“Additionally, the neurosteroid allopregnanolone, which acts as a δGABAAR preferring positive allosteric modulator, has shown some success in recent clinical trials for the treatment of postpartum depression [130].”
From An emerging circuit pharmacology of GABAA receptors (2018) · cites this paper as [130]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
Detection of Postnatal Depression: Development of the 10-item Edinburgh Postnatal Depression Scale
Cox, J. L., Holden, J. M., & Sagovsky, R. (1987) · British Journal of Psychiatry · doi:10.1192/bjp.150.6.782 · Cited by 14,183
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
International Statistical Classification of Diseases and Related Health Problems
Eisfeld, J. (2014) · TSQ: Transgender Studies Quarterly · doi:10.1215/23289252-2399740 · Cited by 3,570
Perinatal Depression: A Systematic Review of Prevalence and Incidence
Gavin, N. I., Gaynes, B. N., Lohr, K. N., Meltzer-Brody, S., Gartlehner, G., & Swinson, T. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000183597.31630.db · Cited by 3,282
Self-citationQuantification of Sleepiness: A New Approach
Hoddes, E., Zarcone, V., Smythe, H., Phillips, R., & Dement, W. C. (1973) · Psychophysiology · doi:10.1111/j.1469-8986.1973.tb00801.x · Cited by 2,538
Cited by
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
“Because of these encouraging findings, brexanolone and SAGE-217 have received breakthrough status from the FDA.”
BackgroundInfluentialMeltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“The second agent is brexanolone, a potent positive allosteric modulator of synaptic and extrasynaptic GABA receptors (Kanes et al., 2017), that has to be administered by intravenous infusion,5 which has been approved for the treatment of postpartum depression in the United States.”
BackgroundNovel and emerging treatments for major depression
Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A. H., & Upthegrove, R. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02080-3 · Cited by 588
Sex differences in depression: Insights from clinical and preclinical studies
Eid, R. S., Gobinath, A. R., & Galea, L. A. M. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.006 · Cited by 457
Metadata
- Authors
- Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., Hoffmann, E., Rubinow, D., Jonas, J., Paul, S., & Meltzer-Brody, S.
- Affiliations
- Sage Therapeutics (United States) (US)
- University of Pennsylvania (US)
- University of Massachusetts Chan Medical School (US)
- Atlanta Center for Medical Research (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Meltzer-Brody, Samantha
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 390
- Issue
- 10093
- Pages
- 480-489
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2626607634
- Cited by
- 479
- References
- 54
- Citations by year
- 2026: 23 · 2025: 43 · 2024: 55 · 2023: 50 · 2022: 35 · 2021: 80 · 2020: 74 · 2019: 69 · 2018: 35 · 2017: 14
- FWCI
- 49.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sage Therapeutics
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy-related medical research
- Keywords
- postpartum depression, brexanolone, allopregnanolone, intravenous infusion, severe depression, maternal mental health, adverse events, dizziness, sleep disorders, antidepressant efficacy, Hamilton Depression Rating Scale, peripartum
- MeSH terms
- Adult, Antidepressive Agents, Double-Blind Method, Drug Combinations, Female, Humans, Infusions, Intravenous, Pregnanolone, Psychiatric Status Rating Scales, Treatment Outcome, Depression, Postpartum, beta-Cyclodextrins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)31264-3
- The paper
- Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., Hoffmann, E., Rubinow, D., Jonas, J., Paul, S., & Meltzer-Brody, S. (2017). Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)31264-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.